CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project develops a universal synthetic chimeric antigen receptor T cell platform to enhance cancer treatment. By utilizing innovative chemistry, it aims to control T cell function and improve effectiveness against solid tumors while reducing manufacturing costs.
Chimeric antigen receptor (CAR) T cell therapy is a promising approach for cancer treatment with remarkable clinical outcomes. CAR T therapy involves the isolation of patients T cells that are genetically modified with an engineered antigen receptor to attack cancer cells.Despite the great promise, the rapid activation and proliferation of CAR T cells can lead to serious side effects.
In addition, CAR T therapy is challenged by limited effectiveness, difficulties in infiltrating solid tumors, ta…
UNIVERSITEIT LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
